Skip to main content
Alnylam Pharmaceuticals, Inc. (ALNY)
NASDAQ: ALNY · Real-Time Price · USD
458.12
-7.22 (-1.55%)
At close: Dec 5, 2025, 4:00 PM EST
451.16
-6.96 (-1.52%)
After-hours: Dec 5, 2025, 7:40 PM EST

Alnylam Pharmaceuticals Revenue

Alnylam Pharmaceuticals had revenue of $1.25B in the quarter ending September 30, 2025, with 149.35% growth. This brings the company's revenue in the last twelve months to $3.21B, up 53.24% year-over-year. In the year 2024, Alnylam Pharmaceuticals had annual revenue of $2.25B with 22.97% growth.

Revenue (ttm)
$3.21B
Revenue Growth
+53.24%
P/S Ratio
18.58
Revenue / Employee
$1,439,493
Employees
2,230
Market Cap
60.52B

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 20242.25B419.95M22.97%
Dec 31, 20231.83B790.87M76.23%
Dec 31, 20221.04B193.13M22.88%
Dec 31, 2021844.29M351.43M71.31%
Dec 31, 2020492.85M273.10M124.28%
Dec 31, 2019 Pro Pro Pro
Dec 31, 2018 Pro Pro Pro
Dec 31, 2017 Pro Pro Pro
Dec 31, 2016 Pro Pro Pro
Dec 31, 2015 Pro Pro Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
UnitedHealth Group 435.16B
Johnson & Johnson 92.15B
Merck & Co. 64.24B
AbbVie 59.64B
Eli Lilly and Company 59.42B
AstraZeneca 58.13B
Novartis AG 56.37B
Novo Nordisk 49.58B
Revenue Rankings

ALNY News

More News